TY -的T1 -大脑自身免疫后单纯疱疹病毒性脑炎(HSE): 100例(S30.004) JF -神经学乔-神经学六世- 88 - 16补充SP - S30.004盟泰国Armangue盟Eugenia马丁首页斯AU -弗朗西斯克格劳盟约瑟Dalmau Y1 - 2017/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/S30.004.abstract N2 -目的:报告引发的自身抗体的临床意义HSE的100名患者。背景:NMDA受体抗体(NMDAR)和其他较少细胞表面抗原已报告post-HSE复发患者的症状。设计/方法:患者前瞻性地确定从全国多中心研究,包括所有新诊断病例HSE (nHSE),和从我们实验室情况下称为自身免疫性脑炎(AE)发生post-HSE。通过免疫组织化学方法确定抗体在老鼠大脑组织,培养神经元,和基于单元的分析。结果:我们发现100例(50 & lt;18年);47是nHSE前瞻性后感染,AE post-HSE 53。12个/ 47(26%)由于AE nHSE也出现复发症状。所有儿童≤3年发展舞蹈手足徐动症有或没有癫痫,而病人比;3年主要显示异常行为(术中;0.001)和最常被误诊为HSE的后遗症。HSE的诊断时,0/47的患者神经元表面抗体。 In contrast, by the time of AE, 56/65 (86%) patients had developed antibodies against the following antigens: NMDAR (n=40; 2 of them with coexisting GABAaR antibodies), unknown cell-surface antigens (15), and GAD65 (1). Among the 35 patients who did not develop AE, 14 (40%) had antibodies in prospective follow-up studies (3 NMDAR, 10 unknown cell-surface, 1 GAD65); in these patients the antibodies were frequently transiently detectable whereas in those with AE the antibodies remained detectable for many months. Overall, detection of NMDAR antibodies after HSE significantly increased the risk of AE (OR 14, IC95%3–75, p<0.01).Conclusions: 26% of patients with HSE develop AE. These patients often have several autoantibodies, among which NMDAR is the most frequently detected. In patients with HSE the subsequent detection of NMDAR antibodies predicts relapsing symptoms due to AE.Study Supported by:Mutua Madrileña Fundation Research Grant, Instituto Carlos III, Madrid (PI14/00203; CM14/00081), Dodot Procter & Gamble research grant sponsored by Asociación Española de Pediatría (AEP) (DN040579, TA), and CIBERERDisclosure: Dr. Armangue has received research support from Mutua Madrileña Foundation. Dr. Martinez-Hernandez has nothing to disclose. Dr. Graus has nothing to disclose. Dr. Dalmau receives royalties from the editorial board of Up-To-Date. Dr. Dalmau has received royalties from a patent from Memorial Sloan-Kettering Cancer Center and royalty payments and/or for technology and invention on NMDAR, GABA(B), GABAaR, DPPX, and IgLON5 antibody test. Dr. Dalmau has received research support from Euroimmun. ER -